Physician profile
Sandra Bialose
NPI 1891305827
$9,188.83
in general payments reported to CMS, 2019-2025
32 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,745 · 2022: $1,426 · 2023: $2,476 · 2024: $2,089 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,018.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,273.12 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,090.12 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,081.75 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $810.27 | 2021-2025 | Caplyta |
| Lundbeck LLC | $638.33 | 2021-2025 | Rexulti |
| Alkermes, INC. | $620.01 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $593.73 | 2021-2024 | Ingrezza |
| Corium, LLC | $473.37 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $355.31 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $259.52 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $255.43 | 2021-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $240.90 | 2023 | Auvelity |
| Supernus Pharmaceuticals, INC. | $218.38 | 2022-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $196.47 | 2021-2025 | Trintellix |
| Neos Therapeutics, LP | $171.49 | 2021-2024 | Adzenys Xr-Odt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.73 | 2024 | Invega Sustenna |
| Bausch Health US, LLC | $107.44 | 2021-2023 | Wellbutrin, Aplenzin |
| Noven Therapeutics, LLC | $104.33 | 2023-2025 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $88.55 | 2021-2022 | |
| Tris Pharma INC | $87.37 | 2022-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $72.39 | 2023-2025 | Loreev Xr |
| Adlon Therapeutics L.P. | $59.96 | 2021 | |
| Indivior INC. | $50.86 | 2021 | |
| Vanda Pharmaceuticals INC. | $44.83 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $34.13 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $33.62 | 2023 | Quviviq |
| Eisai INC. | $20.53 | 2021 | |
| Noven Pharmaceuticals, INC. | $19.60 | 2023 | Xelstrym |
| Owp Pharmaceuticals, INC. | $16.54 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.09 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $15.02 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Bialose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.